Summary & Overview
HCPCS Level II J9303: Panitumumab Injection, 10 mg
HCPCS Level II code J9303 denotes a 10 mg unit of panitumumab injection, a monoclonal antibody used in oncology infusion therapy. Nationally, accurate use of this HCPCS code is important for tracking utilization, ensuring appropriate claims processing, and supporting payment for infused biologic cancer therapies. The code is central to billing in infusion centers and outpatient hospital clinics where panitumumab is administered.
Key payers included in this coverage overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise view of the code’s clinical context and typical sites of service, payer considerations, and the types of benchmarks and policy updates typically relevant to specialty oncology injectables. The publication outlines common billing and coverage themes for oncology biologics, describes what benchmarks payers and providers monitor (such as allowable units, reimbursement policies, and site-of-service differentials), and highlights policy and coding updates that may affect claims processing and utilization management.
Data not available in the input is noted where applicable; the document focuses on national implications rather than state-specific rules.
Billing Code Overview
HCPCS Level II code J9303 represents an injection of panitumumab, billed per 10 mg. This code is used to report the administration of panitumumab, a monoclonal antibody indicated for certain oncology treatments.
-
Service type: Injectable oncology biologic
-
Typical site of service: Infusion center or outpatient hospital infusion clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with metastatic, RAS wild-type colorectal cancer receiving intravenous targeted therapy. The patient presents to an outpatient oncology infusion center for administration of J9303 (panitumumab 10 mg injection) as part of a systemic anti-cancer regimen. Prior to infusion, the oncology nurse verifies identity, checks prior imaging and labs (including current electrolytes, magnesium, and renal/hepatic function), confirms RAS wild-type status in the chart, and reviews prior infusion reactions. The oncology pharmacist compounds the dose based on body surface area or weight per the prescriber's order and institutional protocol. On the day of service a physician or advanced practice provider documents the treatment plan and consents for therapy. The infusion team administers pre-medications if required by institutional protocol, places intravenous access, and infuses J9303 over the recommended infusion time while monitoring for hypersensitivity or dermatologic toxicity. Post-infusion, the patient is observed for immediate reactions, given aftercare instructions regarding skin care and electrolyte monitoring, and scheduled for subsequent cycles. Billing is submitted with J9303 units reflecting the total milligrams administered divided by 10 mg per unit and may include appropriate modifier(s) for circumstances such as repeat service, procedure circumstances, or drug wastage adjustments.
Coding Specifications
| Modifier | Description | When to Use |
|---|